1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight




Combination therapy is set to take centre stage in the treatment of COPD as leading companies such as GlaxoSmithKline (GSK), Boehringer Ingelheim and AstraZeneca vie for market position and share. But will clinicians, payers and patients be persuaded to change from well-established products?


Despite recently approved dual combinations of Long Acting Muscarinic Antagonists (LAMA) and Long Acting Beta2 Agonists (LABA) bringing little novelty to the therapeutic party, companies remained focused on combination approaches. The focus now is on triple combination products, with companies arguing that these will simplify treatment sequencing and provide adherence benefits. But do KOLs agree?

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight provides answers to this question, plus many more. It includes insight and opinion from 12 leading US and European KOLs, presents business-critical insights for branded pharma and the drug discovery community, and highlights what KOLS think about current treatments, and what new therapies will need to demonstrate for the COPD treatment paradigm to change.

KOL Views Covered

LAMAs: Spiriva (Boehringer Ingelheim), Eklira/Tudorzas (AstraZeneca), Seebri (Novartis), Incruse (GSK)
LABAs: Arcapta/Onbrez (Novartis), Striverdi (Boehringer Ingelheim)
LAMA/LABA combinations: Ultibro (Novartis), Anoro (GSK), Duaklir (AstraZeneca)
ICS/LABA combinations, including Seretide/Advair (GSK), Revlar/Breo (GSK), Symbicort (AstraZeneca)
Phosphodiesterase-IV inhibitors, including Daliresp/Daxas (Takeda)
COPD R&D Pipeline: Triple ICS/LABA/LAMA combinations, ICS/LAMA combinations, Anti-IL5 mAbs, PI3K inhibitors, MAPK inhibitors and MABAs







Key Benefits

Know the opinions of KOLs and formulate effective strategies for product positioning and clinician communication
Map new treatment options to COPD patients and patient sub-groups
Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes
Evaluate the changing and challenging competitive landscape



Answers to Critical Questions

Where next for Boehringer Ingelheim’s blockbuster LAMA Spiriva (tiotropium) when it comes under pressure from combination products?
Patient enthusiasm for specific inhaler devices influences prescribing: which are favoured and what are the influences?
What positive outcome from the SUMMIT clinical trial could provide a competitive advantage for GSK’s Revlar/Breo combination?
How might AstraZeneca exploit positive views of its Genuair/Pressair DPI device for Eklira/Tudorza?
Novartis (Ultibro), GSK (Anoro) and AstraZeneca’s Duaklir are locked in battle in the LAMA/LABA sector with Boehringer Ingelheim set to join the fray; but do clinicians see real benefits and what clinical trials could alter perceptions?
What are the prospects for developmental anti-IL5 antibodies, MABAs, PI3K inhibitors and MAPK inhibitors and how do clinicians view them?


Top Takeaways

Know the detailed opinions of leading front line clinicians on current and late stage COPD therapies and what they see as the critical advantages/disadvantages affecting their decision to prescribe
Appreciate the important factors affecting the COPD sector and identify key areas for strategic and tactical action
Understand how new combination therapies will fit into the treatment paradigm and identify the products that will be adversely affected
Review KOL attitudes to important clinical trials such as ATTAIN, ACCORD, GLOW, INVIGORATE, SPARK, ILLUMINATE, FLAME, ACLIFORM, AUGMENT COPD, TONADO 1&2 and SUMMIT


Key Opinion Leaders


North America

Dr Nick Gross, Volunteer Attending Physician, St Francis Hospital, Hartford, CT Professor Richard Casaburi, Professor of Medicine and Associate Chief for Research, Division of Respiratory Medicine, Harbor-UCLA Medical Center, Torrance, California
Dr Barry Make, Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Denver, CO
Dr Donald P. Tashkin, Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles
Dr Edward Eden, Associate Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons, New York
Professor Christopher Cooper, Professor of Medicine and Physiology, David Geffen School of Medicine, University of California, Los Angeles

Europe

Professor Nicolas Roche, Professor, Respiratory Medicine, Paris Descartes University; Department of Respiratory and Intensive Care Medicine, Cochin-Broca-Hôtel-Dieu Hospital Group; Researcher, Paris Descartes University, France
Dr Lipworth, Head, Asthma and Allergy Research Group; Professor, Allergy and Pulmonology at Ninewells Hospital and Medical School, University of Dundee, UK
Professor Peter Barnes, Professor of Thoracic Medicine, National Heart and Lung Institute; Head of Respiratory Medicine, Imperial College; Honorary Consultant Physician, Royal Brompton Hospital, London, UK
Dr Rene Aalbers, Consultant Physician, Respiratory Medicine at Martini Hospital, Groningen, The Netherlands
Anonymous KOL, Germany
Anonymous KOL, Germany



Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, April 2015.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date


Table Of Contents

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
1. Executive summary
2. Research objectives
3. Research focus
4.Current market overview
4.1.Spiriva, Advair/Seretide and Symbicort are the top-selling treatments
4.2.A disease-modifying therapy is the main unmet need
4.3.Spirometry is not widely use

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.